Attorney Docket No. RCK-62

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 0/574 122

In re application of: Axel Bouchon, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/010606

Title: Tetrahydro-Naphthalene and Urea Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

### IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

#### **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted.

William F. Gray Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane, West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459

### IAP5 Rec'd PCT/PTO 3 1 MAR 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		ute for form 1449/P		so, no persons are required t	to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
			-		Application Number	[to be assigned] 574122		
	INIC		ON DIG	CLOSURE	Filing Date	101 71		
					First Named Inventor	Axel Bouchon		
	SI			PPLICANT	Art Unit			
		(Use as man	y sheets as n	ecessary)	Examiner Name			
S	heet	1	of	2	Attorney Docket Number	RCK-62		

	1 04.		U. S. PATENT D			
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<del> </del>	Number-Kind Code <sup>2 (# known)</sup>		<u> </u>	rigules Appear	
		US-				
		US-				
,		US-				
		US-				
		US-				
		US-			,	
		US-				
		US-				
	<del>                                     </del>	US-				
		US-				
		US-				
		US-	<del></del>			
		US-				
	<del>                                     </del>	US-	<del>                                     </del>			
		US-			-	
		US-				
-	T	US-				
		US-	<del></del>			
	<del>                                     </del>	US-	<del> </del>			

		FORE	<b>IGN PATENT DOCU</b>	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τʻ
	F1	WO 2004/052845 A1	06/24/2004	Bayer HealthCare AG		
	F2	WO 03/022809 A2	03/20/2003	SmithKline Beecham P	L.C.	
	F3	WO 03/068749 A1	08/21/2003	Glaxo Group Limited		
	F4	WO 03/014064 A1	02/20/2003	Bayer Aktiengesellscha	ft	
	F5	WO 02/08221 A2	01/31/2002	Neurogen Corporation		
	F5	WO 02/08221 A2	01/31/2002	Neurogen Corporation	<u>-</u>	

Examiner	Date	
Signature	Considered	
•		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

### IAP5 Rec'd PCT/PTO 3 1 MAR 2006

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	[to be assigned] 1 5741	22		
					Filing Date				
					First Named Inventor	Axel Bouchon			
					Art Unit				
(Use as many sheets as necessary)					Examiner Name				
Sheet 2 of 2				2	Attorney Docket Number	RCK-62			
				NON PAT	ENT LITERATURE DOC	UMENTS			
				ook, magazine, joi		of the article (when appropriate), title of alog, etc.), date, page(s), volume-issue try where published.	T <sup>2</sup>		
	R1	Patent Abstract of Japan, Vol. 2003, No. 11, 5 November 2003 (2003-11-05) & JP 2003 192673 A (Bayer AG)							
				·					

	number(s), publisher, city and/or country where published.	ļ
R1	Patent Abstract of Japan, Vol. 2003, No. 11, 5 November 2003 (2003-11-05) & JP 2003 192673 A (Bayer AG)	
		-

	· · · · · · · · · · · · · · · · · · ·		
Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.